Mechanism of bone destruction due to Rheumatoid Arthritis in the fields of Osteoimmunology
骨免疫学领域类风湿关节炎引起的骨破坏机制
基本信息
- 批准号:15390637
- 负责人:
- 金额:$ 9.22万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2003
- 资助国家:日本
- 起止时间:2003 至 2004
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Receptor activator of NF-kB ligand (RANKL) is known to be a key molecule of the osteoimmunology. The aim of this study was to analyze the effect of cell transfer of dedritic cells (DCs) stimulated with RANKL on the development of autoimmune arthropathy in MRL/lpr mice, and to evaluate the possible relationship between autoimmune responses and RANKL-mediated osteoclastogenesis. Matured bone marrow DC (BMDC) from MRL/lpr mice were stimulated with RANKL and chick type II collagen (CII), and were subcutaneously transferred one or three times into MRL/lpr mice. Acceleration of autoimmune arthritis with bone destruction was observed in RANKL/CII DC-transferred mice compared with the legions of non-transferred and non-pulsed DC-transferred, CII DC-transferred MRL/lpr mice. A significant shift to memory phenotypes of T cells was detected in RANKL/CII DC-transferred mice. It was shown that the expressions of MHC class II and RANKL-associated molecules including TRAF6, c-Fms, c-Fos, PU.1 c-Src, of the DCs from RANKL/CII DC-transferred mice were significantly upregulated. In addition, the bone marrow culture from RANKL/CII DC-transferred mice resulted in the increases of osteoclast formation and bone resorption, compared with those of non-DC-transferred mice. On the other hand, three times of transfer of RANKL/CII DC into MRL/lpr mice protected the development of autoimmune arthritis, and reduced the splenomegaly and lymphadenopathy through upregulation of Activation-induced cell death (AICD) of peripheral T cells. These results indicate that RANKL pathway plays a crucial role for immunomodulation of autoimmune arthropathy in a murine model for rheumatoid arthritis.
NF-kB 配体受体激活剂 (RANKL) 被认为是骨免疫学的关键分子。本研究的目的是分析 RANKL 刺激的树突状细胞 (DC) 的细胞转移对 MRL/lpr 小鼠自身免疫性关节病发展的影响,并评估自身免疫反应与 RANKL 介导的破骨细胞生成之间的可能关系。用RANKL和鸡II型胶原蛋白(CII)刺激来自MRL/lpr小鼠的成熟骨髓DC(BMDC),并皮下转移至MRL/lpr小鼠体内一到三次。与大量未转移和非脉冲DC转移的、CII DC转移的MRL/lpr小鼠相比,在RANKL/CII DC转移的小鼠中观察到自身免疫性关节炎和骨破坏的加速。在 RANKL/CII DC 移植小鼠中检测到 T 细胞记忆表型的显着转变。结果显示,RANKL/CII DC 移植小鼠的 DC 中 MHC II 类和 RANKL 相关分子(包括 TRAF6、c-Fms、c-Fos、PU.1 c-Src)的表达显着上调。此外,与非DC移植小鼠相比,RANKL/CII DC移植小鼠的骨髓培养导致破骨细胞形成和骨吸收增加。另一方面,将 RANKL/CII DC 三次转移到 MRL/lpr 小鼠体内可保护自身免疫性关节炎的发展,并通过上调外周 T 细胞的激活诱导细胞死亡 (AICD) 来减少脾肿大和淋巴结肿大。这些结果表明,RANKL 通路在类风湿性关节炎小鼠模型中的自身免疫性关节病的免疫调节中发挥着至关重要的作用。
项目成果
期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A soluble form fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as ah efficient inhibitor for the enhanced osteoblastic differentiation ca used by FGFR2 activation in Apert syndrome.
具有 S252W 突变的可溶性成纤维细胞生长因子受体 2 (FGFR2) 可以作为阿佩尔综合征中 FGFR2 激活增强成骨细胞分化的有效抑制剂。
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Tanimoto Y;Yokozeki M;Hiura K;Moriyama K;et al.
- 通讯作者:et al.
Volume identification of promoter regions involved in cell-and developmental stage-specific osteopontin expression in bone, kidney, placenta, and mammary gland, -An analysis of transgenic mice.
参与骨、肾、胎盘和乳腺中细胞和发育阶段特异性骨桥蛋白表达的启动子区域的体积鉴定,-转基因小鼠的分析。
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Higashibata Y;Sakuma T;Fujihara S;Moriyama K;Nomura S;et al.
- 通讯作者:et al.
Estrogen Deficiency Accelerates Murine Autoimmune Arthritis Associated with RANKL-Mediated Osteoclastogenesis.
雌激素缺乏会加速与 RANKL 介导的破骨细胞生成相关的小鼠自身免疫性关节炎。
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Yoneda T;Izawa T;Moriyama K;Hayashi Y;et al.
- 通讯作者:et al.
Yoneda T, Moriyama K, Hayashi Y., et al.: "Estrogen Deficiency Accelerates Murine Autoimmune Arthritis Associated with RANKL-Mediated Osteoclastogenesis"Endocrinology. (in press).
Yoneda T、Moriyama K、Hayashi Y. 等人:“雌激素缺乏加速与 RANKL 介导的破骨细胞生成相关的小鼠自身免疫性关节炎”内分泌学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Osteoclasis enhance myeloma cell growth and survival via cell-cell contact :: a vicious cycle between bone destruction and myeloma exponsion.
骨质破坏通过细胞间接触增强骨髓瘤细胞的生长和存活:骨破坏和骨髓瘤扩张之间的恶性循环。
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Abe M;Hiura K;Wilde J;Shioyasono A;Moriyama K;Matsumoto T;et al.
- 通讯作者:et al.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MORIYAMA Keiji其他文献
MORIYAMA Keiji的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MORIYAMA Keiji', 18)}}的其他基金
Elucidation of etiology of facial asymmetry based on integrated genome-phenome analysis
基于综合基因组-表型分析阐明面部不对称的病因
- 批准号:
19H03857 - 财政年份:2019
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
International comparative study on craniofacial morphology of Mongolian adolescents
蒙古族青少年颅面形态的国际比较研究
- 批准号:
25305037 - 财政年份:2013
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of new technology for controlling suture remodeling using magnetized liposome with liposome
脂质体磁化脂质体控制缝线重塑新技术的开发
- 批准号:
23659963 - 财政年份:2011
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of new therapeutic strategy for the craniosynostosis patients
颅缝早闭患者新治疗策略的开发
- 批准号:
23390471 - 财政年份:2011
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic study for developing new therapies and its practical use for craniofacial anomalies
颅面异常新疗法开发及其实际应用的基础研究
- 批准号:
18209060 - 财政年份:2006
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
The function of periostin during periodontal tissue remodeling caused by mechanical stress.
骨膜素在机械应力引起的牙周组织重塑过程中的功能。
- 批准号:
13470452 - 财政年份:2001
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Establishment of new treatment for cleft lip and palate patients-basic research for the application of in vitro hybrid artificial bone-
唇腭裂患者新疗法的建立——体外混合型人工骨应用基础研究——
- 批准号:
12557185 - 财政年份:2000
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
REGULATION OF OSTEOCLASTIC BONE RESORPTION BY RHO
RHO 对破骨性骨吸收的调节
- 批准号:
11694283 - 财政年份:1999
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
The Role of MAP Kinase in The Signal Transduction Pathways Activated by Mechanical Stress in Mesenchymal Cells.
MAP 激酶在间充质细胞机械应力激活的信号转导途径中的作用。
- 批准号:
09672094 - 财政年份:1997
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似国自然基金
雌激素受体β通过PGC-1α/CPLX1调控海马齿状回小清蛋白阳性神经元GABA释放在抑郁症发生中的作用和机制
- 批准号:82301722
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
雌激素相关受体γ调控细胞外基质重塑促进小细胞肺癌脑转移的作用机制研究
- 批准号:82304520
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
雌激素通过Nrf2/ATR信号轴调控骨髓间充质干细胞衰老在绝经后骨质疏松中的作用及机制研究
- 批准号:32300981
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
LMX1B通过超级增强子激活基因转录促进雌激素受体阳性乳腺癌发生发展的功能和机制研究
- 批准号:82303108
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向激活雌激素受体β改善LHON遗传病m.3472T>C突变线粒体功能及机制研究
- 批准号:82302086
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Gut microbiome-mediated differences within the pre-malignant mammary tissue environment enhance early breast tumor metastasis
恶变前乳腺组织环境中肠道微生物介导的差异增强了早期乳腺肿瘤转移
- 批准号:
10594667 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Hormone Therapy for Peri- and Postmenopausal Women with HIV (HoT)
感染艾滋病毒的围绝经期和绝经后妇女的激素治疗 (HoT)
- 批准号:
10698682 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Project 3: Primary Prevention and Uterine Preservation in Premenopausal Women with Obesity and Endometrial Hyperplasia/Cancer
项目3:绝经前妇女肥胖和子宫内膜增生/癌症的一级预防和子宫保留
- 批准号:
10711638 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Development of peptide drug conjugates for cancer therapy
开发用于癌症治疗的肽药物缀合物
- 批准号:
10760236 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别: